biosimilars

New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
Cost, adherence as vital as TKI choice for CMLPrice, comorbidities are as important as TKI choice for patients with chronic myeloid leukemia
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Top 5 facts pharmacists should know about biosimilarsConsiderable confusion surrounds the new world of biosimilar drugs. Here are the top five issues connected with biosimilars that pharmacists should know about.
Will biosimilars change the cancer care landscape?While many believe biosimilars have great potential, challenges remain.
Pharm techs, biosimilars, testosterone to be discussed during ASHP online meetingThe role of pharmacy technicians, the naming of biosimilar drugs, and the appropriate use of testosterone are the three major issues that will be discussed during the American Society of Health-System Pharmacists’ (ASHP) first virtual House of Delegates meeting.
[BLOG]: 5 things you need to know about biosimilarsThe first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.
Study: Biosimilars may result in minimal savingsA recent study projects that U.S. employers may see minimal savings to overall healthcare costs resulting from the introduction of biosimilars to the U.S. market.
Biosimilars’ savings could be lower than predictedWhile biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.
First biosimilar in U.S. now availableSandoz announced that Zarxio (filgrastim-sndz), the first biosimilar approved by the FDA in March, is now available in the United States.